CorMedix (NASDAQ:CRMD) has announced strong preliminary unaudited third-quarter financial results and a significant update to its full-year outlook. The company is raising its full-year 2025 pro forma ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results